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Objective: Postsclerotherapy pigmentation occurs in nearly 30% of patients. Hemosiderin, from degradation of the venous
thrombus, is the possible cause. The hypothesis that early removal of the thrombus may eliminate or decrease the
incidence of pigmentation has not been proved or documented. The objective of this study was to investigate the effects
of early microthrombectomy on incidence of postsclerotherapy pigmentation.
Material and methods. This multicenter, randomized, controlled study involved 101 patients with varicose veins (100
women, 1 man; mean age, 46 years [range, 25-68 years]). Patients were divided into two groups, with veins 1 mm or less
in diameter (group 1, n  50) or veins 3 mm or less in diameter (group 2, n  51). Group 1 was treated with Sotradecol
(STD) 0.25%, and group 2 with STD 0.50%. In each patient, an area of varicosities was selected and divided into halves.
One half was randomized to microthrombectomy and the other half served as control. Microthrombectomy was
performed 1 to 3 weeks after treatment in the randomized half. Standard photographs were obtained before and 16 weeks
after treatment, and were evaluated by three independent reviewers who were blinded to treatment assignments. Each
reviewer received an identical set of pretreatment and posttreatment 10 15-cm color photographs of the study area, and
completed a scoring sheet. Average of the scores was used to evaluate primary (pigmentation) and secondary (overall
clinical improvement) end points. The paired t test and chi-square test were used for statistical analysis.
Results: In group 1, microthrombectomized areas had statistically significant less pigmentation (P  .0047) and better
overall clinical improvement scores (P  .0002) compared with the control side. In group 2 there was no significant
difference between the two areas, but patients reported significant relief of pain and inflammation associated with
postsclerotherapy thrombophlebitis.
Conclusion: In veins 1 mm or smaller, microthrombectomy reduced pigmentation and improved overall clinical results. In
veins 3 mm or smaller, statistical significance was not achieved, but thrombectomy resulted in faster resolution of the
postsclerotherapy pain and inflammation. On the basis of these results, microthrombectomy after sclerotherapy is
recommended. (J Vasc Surg 2003;38:896-903.)
Sclerotherapy for treatment of telangectasias and retic-
ular veins of the lower extremities was introduced in the
United States in the late 1920s by McPheeters1 and
Dixon,2 who used a solution of quinine and urethane. Since
then, sclerotherapy has undergone several modifications,
and it is now a safe and effective method for treatment of
various types of varicose veins and other venous problems.
Hyperpigmentation in the treated areas is a common and
undesirable side effect. It has been reported in 30% of
patients who received treatment with sodium tetradecyl
sulfate (Sotradecol, SDT),3-5 a sclerosing agent currently
approved by the US Food and Drug Administration
(FDA). In 80% of patients, the hyperpigmentation disap-
pears spontaneously in 6 to 24 months6,7; however, in a
small number of patients, brownish discoloration persists at
the site of sclerotherapy. The cause of hyperpigmentation is
controversial. Migration of melanine pigment to superficial
skin regions in predisposed patients is assumed to be a
factor.8,9 Recent histologic studies have shown that pig-
mentation is the result of extravasation of erythrocytes into
the epidermis and scattered hemosiderin-laden macro-
phages at the treated site induced by postsclerotherapy
inflammation of the venous endothelium.6,10,11 In persis-
tent cases, laser therapy is recommended.12-14
Our hypothesis is that hemosiderin resulting from deg-
radation of the thrombus formed after the acute sclerother-
apy-induced inflammatory reaction has an important role in
production of pigmentation. Furthermore, it is suggested
that early removal of thrombi (microthrombectomy)
through small stab incisions may prevent or decrease the
incidence and severity of postsclerotherapy hyperpigmen-
tation. Although several authors have reported use of mi-
crothrombectomy to prevent hyperpigmentation, their ob-
servations are anecdotal and not documented.15-18 To our
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knowledge, ours is the first randomized trial to investigate
the effects of microthrombectomy in prevention of
postsclerotherapy pigmentation.
MATERIAL AND METHODS
This was a multicenter, randomized, controlled, paral-
lel study designed to investigate the effect of removal of
intravenous thrombus formed at the site of injection-
sclerotherapy in prevention of pigmentation. The study
complied with the Declaration of Helsinki (1996) and its
amendments regarding investigations in human subjects,
and conformed with good clinical practice. The protocol
was approved by the internal review boards of the research
centers involved. Written informed consent was obtained
from all patients.
A total of 101 patients (100 women, 1 man) with lower
extremity varicosities 3 mm or smaller in diameter were
enrolled and randomized. Patient accrual originated from
the vascular clinics of two university-affiliated medical cen-
ters. Patients were divided into two groups. Group 1 con-
sisted of 50 patients with veins 1 mm or less in diameter
(telangiectasias); group 2 comprised 51 patients with veins
3 mm or less in diameter (reticular veins).
Patient eligibility. Patients were eligible if they had
telangiectasias or reticular veins in the lower extremities,
without valvular incompetence of the saphenous trunks, as
determined with Doppler ultrasound scanning in the up-
right patient. Exclusion criteria included very dark skin
tone, which could make assessment of pigmentation diffi-
cult or impossible; varices greater than 3 mm; pregnancy;
age less than 18 years or greater than 68 years; obesity;
current anticoagulation therapy; or asthma, severe allergy,
acute or generalized systemic disease (cardiac, pulmonary,
hepatic, renal, malignancy, collagen disease), lower-
extremity arterial insufficiency as defined by absent foot
pulses or ankle-brachial index less than 0.7, and acute
superficial or deep venous thrombosis.
Selection of study area. In each patient an area of
varicosity of the lower extremities that could be divided
into two similar halves was selected (Fig 1). For future
identification, the area was drawn on a special sheet of the
Case Report Form containing artist drawings of the four
anatomic aspects of the lower extremities. The two halves
were identified as upper or lower and left or right, depend-
ing on their location in the extremity. In addition, tracings
of varicosities were made on a transparent sheet to facilitate
exact localization of the selected areas during posttreat-
ment visits. Fixed anatomic landmarks, such as knee crease,
moles, freckles, and other forms of identification, were
drawn on the transparent sheet to further assist in recogni-
tion of the treated area. After a computer-generated ran-
domization schedule, one area was assigned to undergo
microthrombectomy, and the other served as control. With
a standardized photographic technique, color photographs
of the selected areas were obtained before and 16 weeks
after treatment.
Sclerotherapy technique. After a preinjection color
photograph of the study area was obtained, varicosities in
both sections of the study area were injected with STD at a
concentration of 0.25% for telangiectasias and 0.50% for
reticular veins. Good illumination, magnification, and asep-
tic technique were standard. Fine hypodermic needles were
used, 30 gauge for telangiectasias and 27 gauge for reticular
veins. Appropriate STD concentrations were prepared by
the hospital pharmacy. The investigator was provided with
1-mL syringes labeled with the protocol-prescribed STD
concentration for the size of vein to be treated. The air-
block technique in an empty vein was used. The entire
study area was injected via several vein punctures, with no
more than 0.5 mL at each site. The total amount of injected
solution was not to exceed 3 mL. After treatment, the
injected area was covered with folded 4  4-inch sponges
held in place with gauze bandages. The leg was then firmly
wrapped from toes to knee or to the groin with 6-inch
elastic bandages. After the initial treatment, patients were
given calf-length or thigh-length elastic stockings (Jobst,
25-30 mm Hg). Compression was maintained continu-
ously for 72 hours in telangiectasias and for 1 week in
reticular veins. Walking was encouraged, and all patients
Fig 1. Preinjection photograph of study area of vein in group 2
(3 mm). Area size was drawn on skin. Label shows patient code
and photograph date.
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were compliant. Treatment of the selected area was accom-
plished in one or two sessions, 1 to 3 weeks apart.
Safety measures. Vital signs were determined before
and immediately after treatment. Immediate local reactions
(pain, inflammation, swelling, allergic reaction), immediate
systemic reactions (dizziness, visual disturbance, nausea,
vomiting, dyspnea, cardiac manifestations, hypotension,
fainting, anaphylactic shock), and delayed local reactions
(local vein thrombosis and its length, ecchymosis, skin
necrosis, hyperpigmentation, and neovascularization [mat-
ting]) were recorded on the Case Report Form after each
visit.
Microthrombectomy technique. Despite appropri-
ate compression, in most patients a thrombus formed in the
injected veins as a result of the endothelial insult. One to 3
weeks after treatment, microthrombectomy was per-
formed, while the thrombus was gelatinous and not yet
organized. After tracing the study area on the transparent
sheet, the assigned randomized half area underwent micro-
thrombectomy, and the other half was left as control. After
skin asepsis, quick mini stab incisions were made 3 to 5 mm
apart along the entire length of the thrombosed vein with a
sterile No. 65 Beaver blade or a microsurgical knife (Fig 2).
Care should be taken to not use a No. 11 blade, because
incisions made with this blade are painful and incision
depth is more difficult to control. Incisions were 1 mm long
along the thrombosed telangiectasias, and 2 mm long in
the case of larger veins. In the larger veins incisions were
made 5 to 10 mm apart. Efforts should be made to incise
only the anterior aspect of the vein wall and avoid through-
and-through incision, which might allow portions of the
clot to migrate deeper during extrusion. The thrombus was
gently extruded between two cotton-tipped swabs or the
gloved fingers of the operator until all trapped clot was
removed. This procedure produced minimal discomfort
and was well tolerated without need for local anesthesia.
The area was then cleansed and covered with sterile com-
pression cushions, and elastic bandages were applied, as
before. Treatment of the selected area was completed in
one or two sessions, 1 to 3 weeks apart. Microthrombec-
tomy was performed at the end of the second treatment in
patients in whom two sessions were necessary. With the
technique described, the procedure takes 10 to 15 minutes,
including dressing the treated area and applying compres-
sion bandages.
Photographic evaluation. Color photographs of the
study area were obtained before and 16 weeks after treat-
ment. An adhesive sticker with the patient’s code number
and date obtained was visible on each photograph. The
photographs were taken by the principal investigator
(J.L.V.) or coinvestigators trained in the technique, with a
Nikon f-4 single lens reflex camera and Kodak Gold 100
ASA film. A black background was used for each
photograph.
Photographs were evaluated by three blinded, indepen-
dent vascular surgeons, who were trained in the evaluation
process by the principal investigator. Each reviewer re-
ceived an identical set of two 10 15 cm photographs, one
obtained before and one obtained 16 weeks after treat-
ment. Following the parameters described below, they
compared the two halves of the study area and completed a
scoring sheet. The average of their scores was used to assess
degree of hyperpigmentation, and overall clinical and cos-
metic results.
Study end points. The objective of this trial was to
compare the effect of microthrombectomy versus non-
microthrombectomy on development of hyperpigmenta-
tion in the same patient. The primary end point was to
Fig 2. Microthrombectomy technique. Mini stab incisions were
made over thrombosed veins 3 to 5 mm apart, with a No. 65
Beaver blade. Thrombi were extruded between two cotton-tipped
swabs.
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determine the degree of hyperpigmentation or brownish
discoloration on a standardized brown scale, where no
pigmentation  4, tan  3, light brown  2, and deep
brown  1. A secondary end point was assessment of
overall clinical improvement by comparing three variables,
including vein disappearance, hyperpigmentation, and neo-
vascularization. The scores of these three variables were the
factors that the reviewers used to evaluate overall clinical
improvement. Clinical improvement was assessed on a scale
of 0 to 10, where 0-2 poor, 2-4 fair, 4-6moderate,
6-8  good, and 8-10  excellent. An average of the
reviewers’ scores was used to assess this end point.
At the end of the study, we asked the patients to
privately fill out a patient satisfaction sheet, expressing their
own degree of satisfaction or dissatisfaction with the treat-
ment. The patient drew a circle around the number that
best represented their assessment of the results: 1  not
satisfied, 2  moderately satisfied, 3  satisfied, and 4 
very satisfied.
Statistical analysis. One hundred one patients were
randomized, and the intent-to-treat principle was applied
for analysis. Analysis was performed for the variables of
pigmentation, overall clinical improvement, vein disappear-
ance, neovascularization, and patient satisfaction, for each
group. Thrombectomized (X) and control areas (Y) were
compared with two statistical methods. Variable X was the
average score of three judges for evaluating corresponding
outcome in the thrombectomized area; variable Y was
similarly defined for the control area. Two statistical meth-
ods were used to compare X and Y. In the first method the
categories were defined as worse (X Y), same (X Y), or
better (X  Y) compared with the control. The chi-square
test was used to assess differences in percentages among the
three categories, or two categories if (better same) versus
worse. In the second method, the paired t test was used to
determine the difference between X and Y (X  Y) was
different from 0. Ninety-five percent confidence interval
(CI) was given for X  Y. Analysis of variance or Cochran-
Mantel-Haenzel test was used to evaluate differences be-
tween the two study centers, adjusted for vein size. Statis-
tical software (version 8.2; SAS Institute, Cary, NC) was
used for the analysis. Significance level was set at 5%.
RESULTS
Patients were enrolled in the study between January
1996 and April 2002. One hundred one patients were
enrolled and randomized (Fig 3). Sixteen patients were
excluded from the analysis. Of those, 11 patients were lost
to follow-up (group 1, n 6; group 2, n 5); in 2 patients
in group 2 no thrombi developed in the injected veins, and
microthrombectomy was not performed; 1 patient in each
group withdrew consent; and for 1 patient in group 1 a
photograph could not be evaluated. Of the remaining 85
patients who completed the study per protocol, 42 were in
group 1 (veins 1 mm) and 43 were in group 2 (veins 3
mm).
There were no changes in vital parameters before and
after treatment. Immediate local adverse events (pain, in-
flammation, swelling) were mild and were expected during
sclerotherapy. There were no immediate systemic adverse
events. Delayed adverse events included thrombosis in the
injected veins and ecchymosis. No patients exhibited skin
necrosis. There were no deaths, and no patient withdrew
from the study because of adverse events. There were no
complications due to microthrombectomy.
Results of the two statistical methods of analysis are
summarized in Tables I and II. In group 1 (veins 1 mm)
the microthrombectomized areas were significantly better
for pigmentation, compared with control areas (57% vs 21%
same, and 21% worse; P  .0047; Table I). For either vein
size, in a higher percentage of patients the microthrom-
bectomized areas were better or the same than the
control areas for the variables of pigmentation, vein
disappearance, neovascularization, and patient satisfac-
tion (Fig 4, A, B). This was true for clinical improvement
Fig 3. Study flow chart.
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(secondary end point), but did not reach statistical sig-
nificance (59.6% vs 40.5% for small veins, 55.9% and
44.2% for larger veins).
In group 1, pigmentation and neovascularization were
significantly better in the treated areas (P .0084) than in
the control areas (P  0.0377; Table II, paired t test).
There were no statistically significant differences in the
other variables between treated and control areas. In the
larger veins in group 2 there was no significant difference
between thrombectomized and control areas (Fig 5, A, B).
Patients, however, consistently reported relief of pain and
discomfort after microthrombectomy.
Mean age between the two study centers did not show
significant difference after adjusting for vein size. A similar
statement is applicable for each study end point.
DISCUSSION
This multicenter, randomized, control trial tested the
effects of early thrombus removal on development of
postsclerotherapy pigmentation in the two most common
vein sizes observed in clinical practice. Sclerotherapy is a
commonly used therapeutic measure for cosmetically un-
wanted telangiectasias and larger varicosities of the lower
extremities. Despite its safety and efficacy in treatment of
vascular blemishes, sclerotherapy has side effects that jeop-
ardize its cosmetic results. Most common side effects are
hyperpigmentation and localized thrombophlebitis; less
common are neovascularization3,19,20 and skin necrosis
due to extravasation or injection into arterioles.3,21 Several
observations have been made regarding incidence and
Table II. Analysis of end point results (paired t test)
Outcome Vein size 1mm (N  42)
P
1  Vein size  3mm (N  43)
PX – Y Mean 95% CI* Mean 95% CI*
Pigmentation 0.29 (0.08, 0.49) .0084† 0.03 (–0.18, 0.24) .7630
Clinical improvement 0.23 (–0.16, 0.63) .2373 0.06 (–0.36, 0.24) .6780
Disappearance 0.10 (–0.05, 0.24) .2045 0.03 (–0.15, 0.09) .6053
Neovascularization 0.17 (0.01, 0.34) .0377* 0.02 (–0.16, 0.19) .8588
X – Y is the difference of averages scores given by the judges for thrombectomized (X) and control areas (Y), where X is the average score of three judges for
evaluating the corresponding outcome in the thrombectomized area, and Y is similarly defined
*Confidence intervals (CI) of 95% were presented for the difference between X and Y (X – Y).
†Significantly different from 0 (P  .05).





1  Vein size  3 mm
(n  43)
PCount % Count %
Pigmentation .0047* .5215
Worse 9 21.4 (.0002) 15 34.9 (.0474)
Same 9 21.4 11 25.6
Better 24 57.1 17 39.5
Clinical improvement .0002* .2420
Worse 17 40.5 (.2170) 19 44.2 (.445)
Same 2 4.8 10 23.3
Better 23 54.8 14 32.6
Patient satisfaction .0001*‡ § .0001*‡
Very satisfied 31 73.8 37 84.1
Satisfied 8 19.1 5 11.4
Moderately satisfied 3 7.1 1 2.3
Unsatisfied 0 0 1 2.3
Disappearance .0302* .0074*
Worse 7 16.7 (.0001)† 9 20.9 (.0001)†
Same 21 50.0 24 55.8
Better 14 33.3 10 23.3
Neovascularization .0464* .2420
Worse 7 16.7 (.0001)† 10 23.3 (.0005)‡
Same 20 47.6 26 60.5
Better 15 35.7 7 16.3
Three categories: worse (X Y), same (X Y), Better (X Y), where X is the average scores of three judges for evaluating the corresponding outcome in the
thrombectomized area, and Y is similarly defined for control area.
*Significant difference among the 3 categorical levels (P  .05, chi-square test).
†Significant difference when Better  Same percentages are compared.
‡Moderately satisfied and unsatisfied were combined to compare with very satisfied and satisfied.
§Intent-to-treat applied.
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cause of hyperpigmentation. Type of sclerosing agent in-
fluences development of pigmentation. The incidence of
hyperpigmentation is 10% to 30% for SDT,3-5 Polidoca-
nol,4,22,23 and hypertonic saline solution.4,24-26 Total body
iron storage is another factor.3 However, Scott and
Seiger27 reported a patient with hemochromatosis treated
with sclerotherapy in whom hyperpigmentation did not
develop despite a significantly elevated serum ferritin level.
Much has been written about the incidence, rate of disap-
pearance, prevention, and treatment of postsclerotherapy
hyperpigmentation. We found only a few anecdotal reports
of the benefit of microthrombectomy in prevention of
hyperpigmentation,3-5 but no prospective, randomized
studies had been carried out to document those observa-
tions. To our knowledge, our study is the first multicenter,
randomized study designed to document the role of
postsclerotherapy thrombus in the genesis of pigmentation,
and the possible benefits of microthrombectomy in preven-
tion of pigmentation.
In our study, early removal of thrombus in sclerosed
veins could prevent or decrease development of hyperpig-
mentation in veins 1 mm or less in diameter and improve
overall clinical and cosmetic results after sclerotherapy. This
supports our hypothesis that, among other factors, throm-
bus has an important role in the cause of postsclerotherapy
hyperpigmentation and that its early removal may decrease
or prevent this adverse event. Removal of thrombus in
larger veins did not result in significant difference between
treated and control areas. A possible explanation for this
observation is that these veins are deeper and the deposits of
hemosiderin are less visible. However, over the course of
the study it was evident that patients experienced consider-
able pain relief and that the induration and phlebitic inflam-
matory process was shorter after thrombectomy. This has
been our experience in management of spontaneous vari-
cophlebitis in patients with large varicose veins of the lower
extremities. During the course of the study, the only side
effects observed were those expected and related to the
sclerotherapy procedure, which proves the safety of micro-
thrombectomy. Some authors15-18 use a No. 11 blade for
the skin mini stab incisions. Use of this blade causes pain,
and we do not recommend it. A microsurgical blade and a
No. 65 Beaver blade are sharper and cause considerably less
pain, and enable more accurate control of the depth and
length of the incision. The procedure was well tolerated by
Fig 4. Pretreatment (A) and posttreatment (B) photographs of telangiectasias. Microthrombectomy was performed
on right side of study area. Three variables used to assess overall clinical improvement were vein disappearance,
pigmentation, and neovascularization. In treated area most veins have disappeared. There is minimal pigmentation, as
compared with control area, and no neovascularization. Treated area was judged better than control area.
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most of our patients, and no local anesthesia was required,
as recommended by some investigators.17
One weakness of our study was the relatively high
incidence of dropouts. This was due to the nature of our
patient population in a military environment. Unforeseen,
sudden assignments out of state accounted for most of the
16 patients lost to follow-up. In two patients thrombi did
not develop in the injected veins, which made it impossible
to perform microthrombectomy. A possible explanation is
that compression after sclerotherapy is more effective in
larger veins.28 Optimal compression over the sclerosed vein
ideally will prevent blood from forming a thrombus by
apposing the vein walls; however, this was not always
achieved. Differences in activity of the fibrinolytic system may
have a role in development of thrombi in some patients.
Another potential drawback of the trial is that the
photographic evaluation made by the independent review-
ers, by its own nature, was subjective. We tried to minimize
this limitation by standardizing the photographic tech-
nique and by using three judges who were blinded to the
identity of the treated area.
By using two different statistical methods to analyze
our results, we support the outcome of our investigation.
Both statistical tests showed that the microthrombecto-
mized area was significantly better than the control area in
smaller veins.
With the advent of laser techniques,29-31 the side ef-
fects of sclerotherapy may be improved. No long-term
studies have evaluated the effects of laser therapy on devel-
opment of hyperpigmentation. Efforts have been made to
treat persistent hyperpigmentation and neovascularization
with laser therapy.31,32 In our opinion, however, it is
preferable to prevent hyperpigmentation by performing
microthrombectomy than to allow its development and
then spend additional time treating it. Other methods,33-35
such as use of different light sources, deferoxamine mesy-
late, and bleaching agents, have had moderate success.
It should be noted that shortly before completion of
this study SDT was withdrawn from the US market for
reasons not disclosed by the manufacturer. At present,
there are no safe and effective sclerosing agents available in
the United States. Hypertonic saline solution 23.4% is not
approved by the FDA as a sclerosant, but it is used exten-
sively in treatment of telangiectasias and small varicosities 1
to 2 mm in diameter. Hypertonic saline solution is not
effective in larger veins. Sodium morrhuate and ethanol-
amine are effective and FDA-approved, but its use is accom-
panied by a relatively high incidence of allergic reactions. A
Fig 5. Pretreatment (A) and posttreatment (B) photographs of veins 3 mm in diameter obtained 18 weeks apart.
Microthrombectomy was performed on lower half. Varicosities have completely disappeared. There is pigmentation in
about two thirds of vein in control area. Overall clinical improvement in treated area was scored as 10 (excellent).
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multicenter, prospective, double-blind study comparing
SDT and Polidocanol was completed, and at the closing of
our trial Polidocanol approval by the FDA was forthcom-
ing. Polidocanol is an effective and safe sclerosing agent,
and when approved it will become the sclerosant of choice.
In summary, early postsclerotherapy microthrombec-
tomyby is a safe, inexpensive, and efficient method for
decreasing or preventing postsclerotherapy hyperpigmen-
tation. In larger veins, it shortens the inflammatory process
and decreases pain.
We thank Drs Mario H. Diaz and James H. Rothstein,
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